Impact of empagliflozin in patients with diabetes and heart failure

David Pham, Natalia De Albuquerque Rocha, Darren K McGuire, Ian J Neeland

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future.

Original languageEnglish (US)
JournalTrends in Cardiovascular Medicine
DOIs
StateAccepted/In press - 2016

Fingerprint

Heart Failure
Type 2 Diabetes Mellitus
Sodium-Glucose Transporter 2
Symporters
empagliflozin
Blood Glucose
Patient Care
Hospitalization
Body Weight
Blood Pressure
Morbidity
Glucose
Mortality
Population

Keywords

  • Empagliflozin
  • Heart failure
  • SGLT2 inhibitor
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of empagliflozin in patients with diabetes and heart failure. / Pham, David; Albuquerque Rocha, Natalia De; McGuire, Darren K; Neeland, Ian J.

In: Trends in Cardiovascular Medicine, 2016.

Research output: Contribution to journalArticle

@article{edd2bf8a8093483ab1111f4b3d1775f1,
title = "Impact of empagliflozin in patients with diabetes and heart failure",
abstract = "Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future.",
keywords = "Empagliflozin, Heart failure, SGLT2 inhibitor, Type 2 diabetes mellitus",
author = "David Pham and {Albuquerque Rocha}, {Natalia De} and McGuire, {Darren K} and Neeland, {Ian J}",
year = "2016",
doi = "10.1016/j.tcm.2016.07.008",
language = "English (US)",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Impact of empagliflozin in patients with diabetes and heart failure

AU - Pham, David

AU - Albuquerque Rocha, Natalia De

AU - McGuire, Darren K

AU - Neeland, Ian J

PY - 2016

Y1 - 2016

N2 - Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future.

AB - Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future.

KW - Empagliflozin

KW - Heart failure

KW - SGLT2 inhibitor

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84995390371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995390371&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2016.07.008

DO - 10.1016/j.tcm.2016.07.008

M3 - Article

C2 - 27612553

AN - SCOPUS:84995390371

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

ER -